Anixa Biosciences, Inc. · NASDAQ:ANIX
Anixa Biosciences — Investor Presentation (March 2023)
22 slides from Anixa Biosciences's investor presentation, Mar 10, 2023
Slide 1: Corporate Presentation March 2023
Amit Kumar, PhD Chairman and CEO ak@anixa.com Mike Catelani President, COO & CFO mceatelani@anixa.com NASDAQ:ANIX Corporate Presentation March 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa Biosciences’ current
Slide 3: Investment Highlights
Investment Highlights Anixa Biosciences is a c al-stage company collaborating with world-renowned institutions to develop first-in-class products to prevent and treat serious, large market diseases Robust Pipeline ighly Diversified ology Pipeline Two Clinical Trials in progress Strong Clinical Data
Slide 4: Unique Business Model: Overview
Unique Business Model: Overview Key Collaborators + Leverage existing infrastructure of partner MOFFITT Vi Strategy: Low-Cost Business Model o Develop programs with partners Cleveland Clinic + Maintain low overhead and cash burn + Allows for multiple orthogonal projects THE pie omogonarrrel WISTAR o
Slide 5: Anixa's Product Pipeline
Anixa's Product Pipeline Current Stage ‘Action | Indication | “OER Upcoming Milestones Partners : Therapeutic |Mechanism of| Geographic [3 Cleveland Breast Ph 1a data release — Q2'23 Ovarian MOFFITT (yj Cancer / Periodic datareleases has Tumors Insite Cleveland Clinie ; Ovarian Oncology vaccine 22"
Slide 6: Breast Cancer Vaccine Program
Breast Cancer Vaccine Program
Slide 7: Breast Cancer Vaccine: Retired Tissue Specific Protein
Breast Cancer Vaccine: Retired Tissue Specific Protein Retired Tissue Specific Protein a-LACTALBUMIN Expressed at periods of life, but no longer expressed as we age * Expressed only in the breast and only during lactation = Expressed in tumor cells, especially Triple Negative Breast Cancer ("TNBC”)
Slide 8: Pre-Clinical Studies: Vaccination Prevents Breast Cancer
Pre-Clinical Studies: Vaccination Prevents Breast Cancer Well-Tolerated Robust Pre-Clinical Response MMTV-neu Mice 100 8 Tumor Size (mm?) 8 8 8 SN 0 Vaceinated Controls Vaccinated mice did not exhibit autoimmune damage, while single T-cell “100% of o-LACTALBUMIN infiltrates were seen in non-lactatin
Slide 9: Breast Cancer Vaccine Phase 1 Trial
Breast Cancer Vaccine Phase 1 Trial Conducted by Cleveland Clinic, Funded by US Department of Defense n open-label, Phase 1 dose-escalation trial Phase ‘a (in progress) Design Phase ‘1b (enrollment open) + Healthy women with BRCA mutations + Each woman decided to undergo prophylactic mastectomy = 18
Slide 10: Breast Cancer Vaccine Clinical Results as of March 2023
Breast Cancer Vaccine Clinical Results as of March 2023 = Enrollment of women who have had TNBC and have undergone standard of care, but are at risk of recurrence = Over a dozen patients dosed = MTD Reached in Q4 2022 = Initial indications show positive immune response as expected and desired = Whil
Slide 11: Breast Cancer Vaccine: A Significant Market Opportunity
Breast Cancer Vaccine: A Significant Market Opportunity + Prophylactic (preventative) vaccines are administered to the total eligible population + We expect reimbursement for this vaccine to be similar to the cervical cancer vaccine (~$400 retail cost) Us. Outside U.S. (Total Eligible Population) @i
Slide 12: Ovarian Cancer CAR-T Program
Ovarian Cancer CAR-T Program
Slide 13: CAR-T Technology: Background and Opportunity
CAR-T Technology: Background and Opportunity Chimeric Antigen Receptor T-cell Our Opportunity = Conventional CAR-T has not worked clinically in solid = Durable responses (50-80% of patients) tumors = Multibillion dollar valuations and big pharma deals o Novartis - First approved product by FDA « Kym
Slide 14: Anixa's Unique and Targeted CAR-T Approach for Solid Tumors
Anixa’s Unique and Targeted CER-T Approach for Solid Tumors Anixa’s CAR-T Program for Ovarian Gancer Follicle Stimulating Hormone Receptor ("FSHR')-mediated CAR-T Technology Chimeric Endocrine Receptor T-Cell FSH Follicle FSHR protein Stimulating (antigen) - found Hormone an only on ovarian cells, T
Slide 15: FSHR Only Expressed in Ovaries and Testes
FSHR ONLY Expressed in Ovaries and Testes in Healthy Humans* 0.0025 5 0.002 - 0.0015 Only in Fetal Thymus Relative FSHR mRNA Expression ° 8 8 8 8 Overy 0 a | PERE CE RE PERTTI e229 PSS ese ee eee eT EEE EEE RE EES ogeseste 88S OS § FORS5 5 a ee s 8 ¢ 5 ea per ge 3B 8g = 2 e 25 88 é cle-stnulting hor
Slide 16: Our FSHR-Mediated CAR-T Technology: Dual Mechanism of Action
Our FSHR-Mediated CAR-T Technology: Dual Mechanism of Action = Many tumors have blood vessels where FSHR is Angiogenesis expressed even though healthy tissue does not show Tumors in apid blood vessel growth to nourish such expression themselves o Physiologically, FSHR may be helpful in enabling tumo
Slide 17: Our FSHR-Mediated CAR-T Program
Our FSHR-Mediated CAR-T Program: The First Potential Anti-Angiogenic CAR-T Therapy Exclusive worldwide license from The Wistar Institute We Believe Our CER-T Approach Will Work In Solid Tumors, Especially Ovarian Cancer, Where Others Have Failed (cullen @ihellianaiess = The CAR-T cells may not be su
Slide 18: Other Programs - Preclinical
Other Programs- preclinical
Slide 19: Ovarian Cancer Vaccine: Retired Tissue Specific Protein
Ovarian Cancer Vaccine: Retired Tissue Specific Protein + Retired Tissue Specific Protein--Expressed at periods of life, but no longer expressed as we age Collaboration with the Cleveland Clinic Funding and Collaboration with The National Cancer Institute «The Extracellular Domain of the Anti-Muller
Slide 20: Latest Reported Financial Summary
Latest Reported Financial Summary = $29.6M cash, cash equivalents and short-term investments as of October 31, 2022 = ~$5-6M annual cash burn since 2017; ~4 years of cash runway o Amit Kumar, Ph.D. Appointed CEO on July 7, 2017 o Current management team and board has managed the company for only a l
Slide 21: Value-Creating Near-Term Clinical Catalysts
Value-Creating Near-Term Clinical Catalysts Multiple catalysts over the next year across our clinical pipeline Program Phase H1 2023 H2 2023 Oncology Breast Cancer Vaccine Phase ta Phase 1a data release Z Preliminary Phase 1b data release subject Breast Cancer Vaccine Phase 1b First dosing to enroll
Slide 22: Investment Highlights
Investment Highlights Anixa Biosciences is a c! al-stage company collaborating with world-renowned institutions to develop first-in-class products to prevent and treat serious, large market diseases Robust Pipeline Strong Clinical Data Large TAM Opportunity Key Partnerships Strong Financial Profile
Anixa Biosciences — Investor Presentation (March 2023) on 6ix